vs
ARTIVION, INC.（AORT）与Doximity, Inc.（DOCS）财务数据对比。点击上方公司名可切换其他公司
Doximity, Inc.的季度营收约是ARTIVION, INC.的1.6倍（$185.1M vs $116.0M），Doximity, Inc.净利率更高（33.3% vs 2.1%，领先31.2%），ARTIVION, INC.同比增速更快（19.2% vs 9.8%），过去两年Doximity, Inc.的营收复合增速更高（25.2% vs 9.1%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
AORT vs DOCS — 直观对比
营收规模更大
DOCS
是对方的1.6倍
$116.0M
营收增速更快
AORT
高出9.4%
9.8%
净利率更高
DOCS
高出31.2%
2.1%
两年增速更快
DOCS
近两年复合增速
9.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $185.1M |
| 净利润 | $2.4M | $61.6M |
| 毛利率 | 63.1% | 89.9% |
| 营业利润率 | 9.2% | 38.9% |
| 净利率 | 2.1% | 33.3% |
| 营收同比 | 19.2% | 9.8% |
| 净利润同比 | 114.7% | -18.1% |
| 每股收益（稀释后） | $0.06 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTDOCS
| Q4 25 | $116.0M | $185.1M | ||
| Q3 25 | $113.4M | $168.5M | ||
| Q2 25 | $113.0M | $145.9M | ||
| Q1 25 | $99.0M | $138.3M | ||
| Q4 24 | $97.3M | $168.6M | ||
| Q3 24 | $95.8M | $136.8M | ||
| Q2 24 | $98.0M | $126.7M | ||
| Q1 24 | $97.4M | $118.1M |
净利润AORTDOCS
| Q4 25 | $2.4M | $61.6M | ||
| Q3 25 | $6.5M | $62.1M | ||
| Q2 25 | $1.3M | $53.3M | ||
| Q1 25 | $-505.0K | $62.5M | ||
| Q4 24 | $-16.5M | $75.2M | ||
| Q3 24 | $-2.3M | $44.2M | ||
| Q2 24 | $-2.1M | $41.4M | ||
| Q1 24 | $7.5M | $40.6M |
毛利率AORTDOCS
| Q4 25 | 63.1% | 89.9% | ||
| Q3 25 | 65.6% | 90.3% | ||
| Q2 25 | 64.7% | 89.2% | ||
| Q1 25 | 64.2% | 89.5% | ||
| Q4 24 | 63.2% | 91.6% | ||
| Q3 24 | 63.7% | 90.0% | ||
| Q2 24 | 64.6% | 89.3% | ||
| Q1 24 | 64.6% | 89.4% |
营业利润率AORTDOCS
| Q4 25 | 9.2% | 38.9% | ||
| Q3 25 | 11.1% | 37.8% | ||
| Q2 25 | 7.4% | 37.4% | ||
| Q1 25 | 2.2% | 35.2% | ||
| Q4 24 | 2.7% | 47.4% | ||
| Q3 24 | 4.6% | 38.8% | ||
| Q2 24 | 6.6% | 36.4% | ||
| Q1 24 | 26.0% | 35.5% |
净利率AORTDOCS
| Q4 25 | 2.1% | 33.3% | ||
| Q3 25 | 5.7% | 36.8% | ||
| Q2 25 | 1.2% | 36.5% | ||
| Q1 25 | -0.5% | 45.2% | ||
| Q4 24 | -16.9% | 44.6% | ||
| Q3 24 | -2.4% | 32.3% | ||
| Q2 24 | -2.2% | 32.7% | ||
| Q1 24 | 7.7% | 34.4% |
每股收益（稀释后）AORTDOCS
| Q4 25 | $0.06 | $0.31 | ||
| Q3 25 | $0.13 | $0.31 | ||
| Q2 25 | $0.03 | $0.27 | ||
| Q1 25 | $-0.01 | $0.31 | ||
| Q4 24 | $-0.40 | $0.37 | ||
| Q3 24 | $-0.05 | $0.22 | ||
| Q2 24 | $-0.05 | $0.21 | ||
| Q1 24 | $0.18 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $64.8M |
| 总债务越低越好 | $215.1M | — |
| 股东权益账面价值 | $448.2M | $979.3M |
| 总资产 | $884.8M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AORTDOCS
| Q4 25 | $64.9M | $64.8M | ||
| Q3 25 | $73.4M | $169.2M | ||
| Q2 25 | $53.5M | $137.3M | ||
| Q1 25 | $37.7M | $209.6M | ||
| Q4 24 | $53.5M | $165.3M | ||
| Q3 24 | $56.2M | $184.2M | ||
| Q2 24 | $55.0M | $111.4M | ||
| Q1 24 | $51.1M | $96.8M |
总债务AORTDOCS
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTDOCS
| Q4 25 | $448.2M | $979.3M | ||
| Q3 25 | $438.7M | $1.1B | ||
| Q2 25 | $419.9M | $1.0B | ||
| Q1 25 | $294.3M | $1.1B | ||
| Q4 24 | $276.2M | $1.0B | ||
| Q3 24 | $304.7M | $961.2M | ||
| Q2 24 | $295.1M | $913.6M | ||
| Q1 24 | $295.0M | $901.4M |
总资产AORTDOCS
| Q4 25 | $884.8M | $1.2B | ||
| Q3 25 | $857.7M | $1.3B | ||
| Q2 25 | $838.4M | $1.2B | ||
| Q1 25 | $791.2M | $1.3B | ||
| Q4 24 | $789.1M | $1.2B | ||
| Q3 24 | $803.1M | $1.1B | ||
| Q2 24 | $789.5M | $1.1B | ||
| Q1 24 | $784.0M | $1.1B |
负债/权益比AORTDOCS
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $60.9M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | — |
| 自由现金流率自由现金流/营收 | -6.9% | — |
| 资本支出强度资本支出/营收 | 23.7% | — |
| 现金转化率经营现金流/净利润 | 8.06× | 0.99× |
| 过去12个月自由现金流最近4个季度 | $839.0K | — |
8季度趋势，按日历期对齐
经营现金流AORTDOCS
| Q4 25 | $19.6M | $60.9M | ||
| Q3 25 | $22.3M | $93.9M | ||
| Q2 25 | $15.0M | $62.1M | ||
| Q1 25 | $-17.0M | $98.5M | ||
| Q4 24 | $10.1M | $65.2M | ||
| Q3 24 | $11.5M | $68.3M | ||
| Q2 24 | $6.1M | $41.2M | ||
| Q1 24 | $-5.5M | $63.9M |
自由现金流AORTDOCS
| Q4 25 | $-7.9M | — | ||
| Q3 25 | $17.7M | — | ||
| Q2 25 | $11.7M | — | ||
| Q1 25 | $-20.6M | — | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $3.6M | — | ||
| Q1 24 | $-9.1M | — |
自由现金流率AORTDOCS
| Q4 25 | -6.9% | — | ||
| Q3 25 | 15.6% | — | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | -20.8% | — | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | 8.2% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -9.3% | — |
资本支出强度AORTDOCS
| Q4 25 | 23.7% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 3.7% | 0.0% | ||
| Q4 24 | 1.5% | 0.0% | ||
| Q3 24 | 3.8% | 0.0% | ||
| Q2 24 | 2.6% | 0.0% | ||
| Q1 24 | 3.7% | 0.0% |
现金转化率AORTDOCS
| Q4 25 | 8.06× | 0.99× | ||
| Q3 25 | 3.42× | 1.51× | ||
| Q2 25 | 11.16× | 1.16× | ||
| Q1 25 | — | 1.58× | ||
| Q4 24 | — | 0.87× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.00× | ||
| Q1 24 | -0.73× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
